Cargando…
Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study
Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity score matching (PSM) examined the efficacy and safety of a supp...
Autores principales: | Chang, Yu-Tang, Chen, Chou-Chen, Chang, Shih-Ching, Chang, Yu-Yao, Lin, Bo-Wen, Chen, Hong-Hwa, Hsieh, Yao-Yu, Hsu, Hung-Chih, Hsieh, Meng-Che, Kuan, Feng-Che, Wu, Chih-Chien, Lu, Wei-Chen, Su, Yu-Li, Liang, Yi-Hsin, Chen, Joe-Bin, Huang, Shuan-Yuan, Huang, Ching-Wen, Wang, Jaw-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346574/ https://www.ncbi.nlm.nih.gov/pubmed/37447297 http://dx.doi.org/10.3390/nu15132971 |
Ejemplares similares
-
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019) -
Comparison of UGT1A1 Polymorphism as Guidance of
Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal
Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line
Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022) -
Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hsieh, Meng-Che, et al.
Publicado: (2021) -
Impact of previous abdominal surgery on robotic-assisted rectal surgery in patients with locally advanced rectal adenocarcinoma: a propensity score matching study
por: Huang, Ching-Wen, et al.
Publicado: (2020) -
Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)